Bengal Physician Journal

Register      Login

VOLUME 11 , ISSUE 2 ( May-August, 2024 ) > List of Articles


Cutaneous Adverse Drug Reactions in a Tertiary Care Hospital: A Record-based Observational Study

Rupak Chatterjee, Kumkum Sarkar, Padi Ampi, Sabina L Joanna Rongong, Shatavisa Mukherjee, Indrashis Podder, Netai Pramanik

Keywords : Adverse drug reactions, Antimicrobials, Cutaneous, Non-steroidal anti-inflammatory drug

Citation Information : Chatterjee R, Sarkar K, Ampi P, Rongong SL, Mukherjee S, Podder I, Pramanik N. Cutaneous Adverse Drug Reactions in a Tertiary Care Hospital: A Record-based Observational Study. Bengal Physician Journal 2024; 11 (2):61-69.

DOI: 10.5005/jp-journals-10070-8045

License: CC BY-NC 4.0

Published Online: 06-07-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Background: Cutaneous adverse drug reactions (CADR) are being frequently reported. However, there is a paucity of epidemiological data in the Indian setting. We aimed to determine the frequency of cutaneous ADR in our setup, identify the causative drug(s), and evaluate their treatment response. Materials and methods: We included the retrospective data of 40 patients with cutaneous drug reactions. Available history including medication history was taken and causality was determined. Descriptive statistics were used for data analysis. Results: The most common offending drugs were antimicrobials followed by non-steroidal anti-inflammatory drugs (NSAIDs)/DMARDs. Among antimicrobials, fluoroquinolones were the commonest culprit. The maculopapular rash was the commonest manifestation seen in 50% of cases followed by fixed drug eruption (FDE) in 15% of total cases. Three cases of Stevens–Johnson Syndrome (SJS) were noted in our study. Levofloxacin was the offending drug in one case and rest two cases were due to cephalosporins. Conclusion: Awareness is needed about the common causative agents of CADR, and these drugs must not be prescribed irrationally. Detailed medication history and clinico-pharmacological evaluation are extremely important for approaching any patient with CADR.

PDF Share
  1. Roujeau JC, Allanore L, Liss Y, et al. Severe cutaneous adverse reactions to drugs (SCAR): Definitions, diagnostic criteria, genetic predisposition. Dermatol Sin 2009;27:203–209.
  2. Li LF, Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol 2006;31:642–647. DOI: 10.1111/j.1365-2230.2006.02185.x.
  3. Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2010;49:834–841. DOI: 10.1111/j.1365-4632.2010.04481.x.
  4. Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Indian J Dermatol Venereol Leprol 2012;78:734–739. DOI: 10.4103/0378-6323.102367.
  5. Zhong H, Zhou Z, Wang H, et al. Prevalence of cutaneous adverse drug reactions in Southwest China: An 11-year retrospective survey on in-patients of a dermatology ward. Dermatitis 2012;23:81–85. DOI: 10.1097/DER.0b013e31823d1aae.
  6. Sharma VK, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents – A 6 year series from Chandigarh, India. J Postgrad Med 2001;47:95–99. PMID: 11832597.
  7. The Use of the WHO-UMC System for Standardised Case Causality Assessment. Available from: Accessed on 01.02.2023.
  8. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245. DOI: 10.1038/clpt.1981.154.
  9. Sharma VK, Dhar S. Clinical pattern of cutaneous drug eruption among children and adolescents in North India. Pediatr Dermatol 1995;12:178–183. DOI: 10.1111/j.1525-1470.1995.tb00149.x.
  10. Blacker K, Stern R, Wintroub BU. Cutaneous reaction to drugs. In: Fitzpatrick T Eisen A, Wolft K, editors. Dermatology in general medicine. New York: McGraw Hill; 1993, pp. 1783–1784.
  11. Bookar HE. Idiosyncratic reactions to anti-epileptic drugs. Epilepsia 1975;16:171–181. DOI: 10.1111/j.1528-1157.1975.tb04733.x.
  12. Gordin FN, Simon GL, Wofsy CD. Adverse reactions to trimethoprim-sulphamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495–499. DOI: 10.7326/0003-4819-100-4-495.
  13. Schofield JK, Tatnali FM, Brown J. Recuurent erythema multiforme: Tissue typing in a large series of patients. Br J Dermatol 1994;131:532–535. DOI: 10.1111/j.1365-2133.1994.tb08555.x.
  14. Pellicano R, Ciavarelia G, Lomuto M, et al. Genetic susceptibility to fixed drug eruption. Evidence of link with HLA B22. J Am Acad Dermatol 1994;30:52–54. DOI: 10.1016/s0190-9622(94)70007-9.
  15. Leape LL, Brennan TA, Laird N. The nature of adverse events in hospitalised patients: Results of the Harvard Medical Practice Study II. N Engl J Med 1991;324:377–384. DOI: 10.1056/NEJM199102073240605.
  16. Sharnma VK, Sethuraman G. Adverse cutaneous reactions to drugs: An overview. J Postgra Med 1996;42(1):15–22. PMID: 9715291.
  17. Chatterjee S, Ghosh AP, Barbhuiya J, et al. Adverse cutaneous drug reactions: A one year survey at a dermatology outpatient clinic of a tertiary care hospital. Indian J Pharmacol 2006;38:429–431. DOI: 10.4103/2229-5178.156384.
  18. Ashifha S, Vijayashree J, Vudayana K, et al. A study of cutaneous adverse drug reactions at a tertiary care center in Andhra Pradesh, India. Cureus 2023;15(4):e37596. DOI: 10.7759/cureus.37596.
  19. Ardern-Jones MR, Friedmann PS. Skin manifestations of drug allergy. Br J Clin Pharmacol 2011;71(5):672–683. DOI: 10.1111/j.1365-2125.2010.03703.x.
  20. Samajdar SS, Mukherjee S, Tripathi SK, et al. Deprescribing for better patient outcomes in chronic long term care and role of clinical pharmacological review. J Assoc Physicians India 2021;69(11):11–12. PMID: 34781620.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.